Following a resubmission
salmeterol/fluticasone 50/500 micrograms inhaler (Seretide 500 Accuhaler) is not recommended for use within NHS Scotland for the symptomatic treatment of patients with chronic obstructive airways disease (COPD) with a forced expiratory volume in 1 second (FEV1) 50% to <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
While there were improvements in lung function tests and reductions in moderate exacerbations with the salmeterol/fluticasone combination compared to placebo and to salmeterol alone, there were no significant differences in mortality rates over 3 years. In addition, the manufacturer did not present a sufficiently robust economic case to gain acceptance by SMC.
Download detailed advice114KB (PDF)
Medicine details
- Medicine name:
- salmeterol xinafoate fluticasone propionate combination inhaler (Seretide)
- SMC ID:
- 450/08
- Indication:
- Symptomatic treatment of patients with chronic obstructive pulmonary disease (COPD)
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Resubmission
- Status
- Not recommended
- Date advice published
- 12 January 2009